@article{608b492c6bf043659288a821f79c070c,
title = "The first European interdisciplinary Ewing sarcoma research summit",
abstract = "The European Network for Cancer Research in Children and Adolescents (ENCCA) provides an interaction platform for stakeholders in research and care of children with cancer. Among ENCCA objectives is the establishment of biology-based prioritization mechanisms for the selection of innovative targets, drugs, and prognostic markers for validation in clinical trials. Specifically for sarcomas, there is a burning need for novel treatment options, since current chemotherapeutic treatment protocols have met their limits. This is most obvious for metastatic Ewing sarcoma (ES), where long term survival rates are still below 20%. Despite significant progress in our understanding of ES biology, clinical translation of promising laboratory results has not yet taken place due to fragmentation of research and lack of an institutionalized discussion forum. To fill this gap, ENCCA assembled 30 European expert scientists and five North American opinion leaders in December 2011 to exchange thoughts and discuss the state of the art in ES research and latest results from the bench, and to propose biological studies and novel promising therapeutics for the upcoming European EWING2008 and EWING2012 clinical trials.",
keywords = "Animal models, Biomarkers, Drug screen, Epigenetics, Ewing sarcoma, Genomics, Prognosis, Sarcomagenesis",
author = "Heinrich Kovar and Javier Alonso and Pierre Aman and Aryee, {Dave N.T.} and Jozef Ban and Burchill, {Sue A.} and Stefan Burdach and {De Alava}, Enrique and Olivier Delattre and Uta Dirksen and Argyro Fourtouna and Simone Fulda and Helman, {Lee J.} and David Herrero-Martin and Pancras, {Pancras C.} and Udo Kontny and Lawlor, {Elizabeth R.} and Lessnick, {Stephen L.} and Antonio Llombart-Bosch and Markus Metzler and Richard Moriggl and Stephan Niedan and Jenny Potratz and Fran{\c c}oise Redini and G{\"u}nther, {G{\"u}nther H.} and Riedmann, {Lucia T.} and Claudia Rossig and Sch{\"a}fer, {Beat W.} and Raphaela Schwentner and Katia Scotlandi and Sorensen, {Poul H.} and Staege, {Martin S.} and Franck Tirode and Jeffrey Toretsky and Selena Ventura and Angelika Eggert and Ruth Ladenstein",
note = "Funding Information: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Andrea George, Laurie M. Billing, Libby Reeg, Alexander Kohrman, Andrew Weigel, Kenzie Teno, and Jess Shiltz report grant funding from the Council of State and Territorial Epidemiologists. William Schaffner reports personal fees from VBI Vaccines. Evan J. Anderson reports grants for clinical trials from Pfizer, Merck, PaxVax, Micron, Sanofi-Pasteur, Janssen, MedImmune and GSK, and personal fees for consulting from Sanofi-Pasteur, Pfizer, and Medscape, and for data safety monitoring board service from Kentucky Bioprocessing, Inc. and Sanofi-Pasteur; and funding from the National Institutes of Health to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. No other potential conflicts of interest were disclosed.",
year = "2012",
doi = "10.3389/fonc.2012.00054",
language = "English (US)",
volume = "2 MAY",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
}